ES2194203T3 - Ligando del receptor tie-2 (ligando-4 de tie) y su uso. - Google Patents

Ligando del receptor tie-2 (ligando-4 de tie) y su uso.

Info

Publication number
ES2194203T3
ES2194203T3 ES97930162T ES97930162T ES2194203T3 ES 2194203 T3 ES2194203 T3 ES 2194203T3 ES 97930162 T ES97930162 T ES 97930162T ES 97930162 T ES97930162 T ES 97930162T ES 2194203 T3 ES2194203 T3 ES 2194203T3
Authority
ES
Spain
Prior art keywords
tie
procedure
growth
binding
receiver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97930162T
Other languages
English (en)
Inventor
David M Valenzuela
Pamela F Jones
George D Yancopoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/665,926 external-priority patent/US5851797A/en
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2194203T3 publication Critical patent/ES2194203T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C07K14/17—Porcine transmissible gastroenteritis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA UNA MOLECULA DE ACIDO NUCLEICO AISLADA, QUE CODIFICA PARA UN MIEMBRO DE LA FAMILIA DE LIGANDOS TIE. LA INVENCION PROPORCIONA ASIMISMO UNA MOLECULA DE ACIDO NUCLEICO AISLADA QUE CODIFICA PARA EL LIGANDO TIE-3 O TIE4. ASIMISMO, SE PROPORCIONA UN ANTICUERPO QUE SE UNE ESPECIFICAMENTE A DICHOS LIGANDOS, Y UN ANTAGONISTA DE TIE; COMPOSICIONES TERAPEUTICAS ASI COMO UN PROCEDIMIENTO PARA BLOQUEAR EL CRECIMIENTO DE LOS VASOS SANGUINEOS, UN PROCEDIMIENTO PARA FAVORECER LA NEOVASCULARIZACION; UN PROCEDIMIENTO PARA INCREMENTAR EL CRECIMIENTO O DIFERENCIACION DE UNA CELULA QUE EXPRESA EL RECEPTOR TIE; UN PROCEDIMIENTO PARA BLOQUEAR EL CRECIMIENTO O DIFERENCIACION DE UNA CELULA QUE EXPRESA EL FACTOR TIE; Y UN PROCEDIMIENTO PARA ATENUAR O PREVENIR EL CRECIMIENTO TUMORAL EN HUMANOS.
ES97930162T 1996-06-19 1997-06-19 Ligando del receptor tie-2 (ligando-4 de tie) y su uso. Expired - Lifetime ES2194203T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/665,926 US5851797A (en) 1996-06-19 1996-06-19 Tie ligand-3, methods of making and uses thereof
US2108796P 1996-07-02 1996-07-02
US2299996P 1996-08-02 1996-08-02

Publications (1)

Publication Number Publication Date
ES2194203T3 true ES2194203T3 (es) 2003-11-16

Family

ID=27361571

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97930162T Expired - Lifetime ES2194203T3 (es) 1996-06-19 1997-06-19 Ligando del receptor tie-2 (ligando-4 de tie) y su uso.

Country Status (20)

Country Link
US (2) US6432667B1 (es)
EP (1) EP0939809B1 (es)
JP (1) JP2000513932A (es)
KR (1) KR20000022028A (es)
CN (1) CN1227603A (es)
AT (1) ATE235551T1 (es)
AU (1) AU724467B2 (es)
CA (1) CA2258526A1 (es)
CZ (1) CZ421898A3 (es)
DE (1) DE69720241T2 (es)
DK (1) DK0939809T3 (es)
ES (1) ES2194203T3 (es)
FI (1) FI982745L (es)
HU (1) HUP0004320A3 (es)
IL (1) IL127623A0 (es)
NO (1) NO985904L (es)
NZ (1) NZ333374A (es)
PL (1) PL330705A1 (es)
PT (1) PT939809E (es)
WO (1) WO1997048804A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350450B1 (en) 1997-09-19 2002-02-26 Genentech, Inc. TIE ligand homologue antibody
US6057435A (en) 1997-09-19 2000-05-02 Genentech, Inc. Tie ligand homologues
US5972338A (en) 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US6348350B1 (en) 1997-09-19 2002-02-19 Genentech, Inc. Ligand homologues
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
AU4643699A (en) * 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
EP1508337A3 (en) * 1998-11-20 2006-04-19 Genentech, Inc. Uses for eph receptor antagonists and agonists to treat vascular disorders
ES2242437T3 (es) * 1998-11-20 2005-11-01 Genentech, Inc. Utilizaciones de agonistas y antagonistas del receptor eph para el tratamiento de trastornos vasculares.
CA2354846A1 (en) 1998-12-23 2000-06-29 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of ligands
AU2002335085A1 (en) 2001-10-25 2003-05-06 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
US7296991B2 (en) * 2004-12-10 2007-11-20 Irwin Jere F Adjustable extruder die assembly die lip adjustment apparatus
US20080119367A1 (en) * 2004-12-17 2008-05-22 Mayo Foundation For Medical Education And Research Prognosis of Renal Cell Carcinoma
WO2007030658A2 (en) * 2005-09-08 2007-03-15 Children's Hospital Medical Center Compositions useful for and methods of modulating angiogenesis
US20080080059A1 (en) * 2006-09-28 2008-04-03 Pacific Biosciences Of California, Inc. Modular optical components and systems incorporating same
US11077112B2 (en) 2015-09-29 2021-08-03 ProdrugXtend Pty Ltd Formulation and treatment methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
AU4651893A (en) 1992-06-26 1994-01-24 Immunex Corporation Novel tyrosine kinase
CN1173991C (zh) 1992-11-13 2004-11-03 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k-1
US5643755A (en) * 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
US5814464A (en) * 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
WO1996020403A1 (en) * 1994-12-23 1996-07-04 Ludwig Institute For Cancer Research Assay, receptor proteins and ligands
CA2216963C (en) * 1995-04-06 2010-06-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligands, methods of making and uses thereof
US5851797A (en) * 1996-06-19 1998-12-22 Regeneron Pharmaceuticals, Inc. Tie ligand-3, methods of making and uses thereof

Also Published As

Publication number Publication date
PL330705A1 (en) 1999-05-24
WO1997048804A3 (en) 1998-04-09
PT939809E (pt) 2003-08-29
DE69720241T2 (de) 2003-12-11
FI982745A7 (fi) 1999-02-04
ATE235551T1 (de) 2003-04-15
AU3406197A (en) 1998-01-07
US20030064470A1 (en) 2003-04-03
CA2258526A1 (en) 1997-12-24
DK0939809T3 (da) 2003-07-21
HUP0004320A2 (hu) 2001-06-28
EP0939809A2 (en) 1999-09-08
EP0939809B1 (en) 2003-03-26
AU724467B2 (en) 2000-09-21
FI982745A0 (fi) 1998-12-18
NO985904D0 (no) 1998-12-16
DE69720241D1 (de) 2003-04-30
WO1997048804A2 (en) 1997-12-24
JP2000513932A (ja) 2000-10-24
KR20000022028A (ko) 2000-04-25
CZ421898A3 (cs) 1999-05-12
NO985904L (no) 1999-02-19
HUP0004320A3 (en) 2005-11-28
NZ333374A (en) 2000-06-23
CN1227603A (zh) 1999-09-01
US6881395B2 (en) 2005-04-19
US6432667B1 (en) 2002-08-13
FI982745L (fi) 1999-02-04
IL127623A0 (en) 1999-10-28

Similar Documents

Publication Publication Date Title
ES2154354T3 (es) Ligandos tie-2, metodos para obtenerlos y sus usos.
ES2058083T3 (es) Anticuerpos monoclonales contra el factor humano de la necrosis tumoral (tnf) y su empleo.
TR200100149T2 (tr) Dual anjiyotensin endotelin alıcı antagonistleri olarak bifenil-sülfonamitler
BR0306444A (pt) Uso de anticorpos anti-tnf(alfa) e outra droga
AR027060A1 (es) Bases de mannich de 1-naftol y 2-naftol sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos, asi como el uso deestos compuestos para la fabricacion de medicamentos
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
CR8673A (es) Compuestos de difenil-ox-indol-2-ona y su uso en el tratamiento del cancer
MX9307974A (es) Nuevos derivados de acido hidroxiiminoalquilindolcarboxilico, su obtencion y uso.
BRPI0510716A (pt) uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit
EA200000251A1 (ru) Производные резорцинола
ES2153483T3 (es) Metodos y composiciones para la coagulacion especifica en los vasos tumorales.
EA200200530A1 (ru) Гетероциклические замещенные пиразолоны
EA199800563A1 (ru) Антагонисты гормона, высвобождающего гонадотропин
CR10147A (es) "ligandos que tienen especificidad de enlace para vegf y/o egfr y métodos de uso de los mismos"
AR030760A1 (es) Nuevos acidos y polipeptidos nucleicos receptores
SV2002000249A (es) Derivados de tiazolilamida ref, lea 34082-sv
CY1114944T1 (el) Σταθεροποιημενα αλφα ελικοειδη πεπτιδια και χρησεις αυτων
EE200200621A (et) Kasvaja nekroosifaktori sarnase apoptoosi-indutseeriva ligandi retseptori suhtes selektiivne antikeha ja selle kasutamine
ES2126618T3 (es) Procedimiento para el aislamiento y cultivo de celulas transformadas asi como empleo de estas celulas para la obtencion de anticuerpos especificos para el individuo.
FI982745A0 (fi) TIE-2-reseptoriligandit (TIE-ligandi-3; TIE-ligandi-4) ja niiden käyttö
TR200102742T2 (tr) Rezorsinol türevleri
CO5150178A1 (es) Bromohidrato de eletriptan monohidrato y procedimiento para su preparacion
ES2156639T3 (es) Producto de revestimiento de dos componentes y procedimiento de preparacion.
ATE259886T1 (de) Ledergerben
EA200300756A1 (ru) Андрогенные 7-замещенные-11-галогенированные стероиды